8,041 reports of this reaction
4.3% of all MACITENTAN reports
#2 most reported adverse reaction
HEADACHE is the #2 most commonly reported adverse reaction for MACITENTAN, manufactured by Actelion Pharmaceuticals US, Inc.. There are 8,041 FDA adverse event reports linking MACITENTAN to HEADACHE. This represents approximately 4.3% of all 188,657 adverse event reports for this drug.
Patients taking MACITENTAN who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is moderately reported among MACITENTAN users, representing a notable but not dominant share of adverse events.
In addition to headache, the following adverse reactions have been reported for MACITENTAN:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 8,041 FDA reports for MACITENTAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 4.3% of all adverse event reports for MACITENTAN, making it one of the most commonly reported side effect.
If you experience headache while taking MACITENTAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.